If you want to find out more about how FIECON delivers results, get in touch.

More case studies



  • Adapting two global models for local HTA submission in an Oncology indication
  • Adapt a global model and identify additional comparators (based on the local market) and incorporate a societal perspective
Respecting the technical:
  • Global model was originally built for the UK, despite Canada being the first market for launch
  • The product was being submitted for two indications concurrently
  • Required assessment by two HTA agencies in Canada (CADTH and INESS)
Delivering the practical:
  • Incorporated cost and survival data from a recently completed RWE initiative
  • Additional comparators and a societal perspective added, tailored to CADTH (Canada) and INESS (Quebec province)
  • Held model validation sessions with a cross functional client team (HEOR, medical affairs and market access attendees)
  • Updated treatment pathways, comparators, long term efficacy, and economic data

  • 4 total models delivered (1 each for CADTH and INESS in indications 1 & 2)
  • 4 total technical reports delivered.
  • Delivered report on recommendations for value communication in Canada, as well as adaptations to future markets
Acronyms: RWE, Real World Evidence; HTA, Health Technology Assessment; HEOR, Health Economics and Outcomes Research; CADTH, Canadian Agency for Drugs and Technologies in Health; INDESS, Institut national d’excellence en santé et en services sociaux (Institute of national excellence in health and social services).